On the public citation graph

MEK and PI3K inhibition in solid tumors: rationale and evidence to date

https://doi.org/10.1177/1758834015571111
0 signed · 189 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/path.1790openalex-snapshot
Copy number amplification of 3q26–27 oncogenes in microdissected oral squamous cell carcinoma and oral brushed samples from areca chewers
inferredcites →https://doi.org/10.1007/s10637-010-9392-8openalex-snapshot
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
inferredcites →https://doi.org/10.1016/0092-8674(88)90571-5openalex-snapshot
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
inferredcites →https://doi.org/10.1016/j.ccr.2009.04.012openalex-snapshot
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
inferredcites →https://doi.org/10.1016/j.ccr.2010.10.031openalex-snapshot
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
inferredcites →https://doi.org/10.1016/j.ccr.2012.11.007openalex-snapshot
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
inferredcites →https://doi.org/10.1016/j.cell.2011.02.013openalex-snapshot
Hallmarks of Cancer: The Next Generation
inferredcites →https://doi.org/10.1016/j.tibs.2011.03.006openalex-snapshot
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
inferredcites →https://doi.org/10.1016/s0140-6736(08)61039-9openalex-snapshot
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
inferredcites →https://doi.org/10.1016/s0140-6736(12)60868-xopenalex-snapshot
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(12)70270-xopenalex-snapshot
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
inferredcites →https://doi.org/10.1038/nature00766openalex-snapshot
Mutations of the BRAF gene in human cancer
inferredcites →https://doi.org/10.1038/nature04304openalex-snapshot
BRAF mutation predicts sensitivity to MEK inhibition
inferredcites →https://doi.org/10.1038/nature07385openalex-snapshot
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
inferredcites →https://doi.org/10.1038/nature08902openalex-snapshot
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
inferredcites →https://doi.org/10.1038/nature09454openalex-snapshot
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
inferredcites →https://doi.org/10.1038/nature11252openalex-snapshot
Comprehensive molecular characterization of human colon and rectal cancer
inferredcites →https://doi.org/10.1038/nature11404openalex-snapshot
Comprehensive genomic characterization of squamous cell lung cancers
inferredcites →https://doi.org/10.1038/nature11412openalex-snapshot
Comprehensive molecular portraits of human breast tumours
inferredcites →https://doi.org/10.1038/nature12113openalex-snapshot
Integrated genomic characterization of endometrial carcinoma
inferredcites →https://doi.org/10.1038/nature13385openalex-snapshot
Comprehensive molecular profiling of lung adenocarcinoma
inferredcites →https://doi.org/10.1038/nature13480openalex-snapshot
Comprehensive molecular characterization of gastric adenocarcinoma
inferredcites →https://doi.org/10.1038/ng.619openalex-snapshot
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
inferredcites →https://doi.org/10.1038/nm.1890openalex-snapshot
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
inferredcites →https://doi.org/10.1038/nrclinonc.2013.155openalex-snapshot
Molecular targets on the horizon for kidney and urothelial cancer
inferredcites →https://doi.org/10.1038/nrg1879openalex-snapshot
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
inferredcites →https://doi.org/10.1038/onc.2010.626openalex-snapshot
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
inferredcites →https://doi.org/10.1038/onc.2011.42openalex-snapshot
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
inferredcites →https://doi.org/10.1038/sj.bjc.6603291openalex-snapshot
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
inferredcites →https://doi.org/10.1053/j.seminoncol.2006.04.002openalex-snapshot
Role of Raf Kinase in Cancer: Therapeutic Potential of Targeting the Raf/MEK/ERK Signal Transduction Pathway
inferredcites →https://doi.org/10.1056/nejmoa060655openalex-snapshot
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa066838openalex-snapshot
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa0708857openalex-snapshot
Sorafenib in Advanced Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1009290openalex-snapshot
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
inferredcites →https://doi.org/10.1056/nejmoa1103782openalex-snapshot
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
inferredcites →https://doi.org/10.1056/nejmoa1105358openalex-snapshot
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
inferredcites →https://doi.org/10.1056/nejmoa1109653openalex-snapshot
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1208958openalex-snapshot
Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
inferredcites →https://doi.org/10.1056/nejmoa1209288openalex-snapshot
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
inferredcites →https://doi.org/10.1056/nejmoa1210093openalex-snapshot
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
inferredcites →https://doi.org/10.1073/pnas.0905056106openalex-snapshot
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
inferredcites →https://doi.org/10.1073/pnas.0905152106openalex-snapshot
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
inferredcites →https://doi.org/10.1073/pnas.0907325106openalex-snapshot
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
inferredcites →https://doi.org/10.1111/j.1464-410x.2010.09470.xopenalex-snapshot
PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer
inferredcites →https://doi.org/10.1158/0008-5472.can-05-2925openalex-snapshot
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
inferredcites →https://doi.org/10.1158/0008-5472.can-11-1515openalex-snapshot
Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
inferredcites →https://doi.org/10.1158/0008-5472.can-11-3747openalex-snapshot
MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-0317openalex-snapshot
In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-2436openalex-snapshot
Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-3529openalex-snapshot
Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-0978openalex-snapshot
Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-0341openalex-snapshot
Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations
inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-1814openalex-snapshot
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
inferredcites →https://doi.org/10.1158/1535-7163.mct-08-0013openalex-snapshot
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
inferredcites →https://doi.org/10.1158/2159-8290.cd-13-0315openalex-snapshot
mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
inferredcites →https://doi.org/10.1159/000353099openalex-snapshot
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
inferredcites →https://doi.org/10.1159/000453569openalex-snapshot
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
inferredcites →https://doi.org/10.1159/000462153openalex-snapshot
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.
inferredcites →https://doi.org/10.1172/jci44145openalex-snapshot
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
inferredcites →https://doi.org/10.1186/1471-2407-12-612openalex-snapshot
Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
inferredcites →https://doi.org/10.1186/1741-7015-10-161openalex-snapshot
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
inferredcites →https://doi.org/10.1200/jco.2004.01.185openalex-snapshot
Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer
inferredcites →https://doi.org/10.1200/jco.2007.14.4956openalex-snapshot
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
inferredcites →https://doi.org/10.1200/jco.2011.29.15_suppl.3021openalex-snapshot
A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.
inferredcites →https://doi.org/10.1200/jco.2011.36.1360openalex-snapshot
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
inferredcites →https://doi.org/10.1200/jco.2012.30.15_suppl.2566openalex-snapshot
A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors.
inferredcites →https://doi.org/10.1200/jco.2012.30.15_suppl.3003openalex-snapshot
A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.
inferredcites →https://doi.org/10.1200/jco.2014.32.15_suppl.2588openalex-snapshot
A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer.
inferredcites →https://doi.org/10.1200/jco.2014.32.15_suppl.9051openalex-snapshot
A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.
inferredcites →https://doi.org/10.17615/hvp3-wg08openalex-snapshot
Integrated genomic analyses of ovarian carcinoma
inferredcites →https://doi.org/10.17615/za09-dk57openalex-snapshot
Comprehensive molecular characterization of urothelial bladder carcinoma
inferredcites →https://doi.org/10.2174/092986708784638825openalex-snapshot
Farnesyltransferase Inhibitors: A Detailed Chemical View on an Elusive Biological Problem
inferredcites →https://doi.org/10.2174/1568026053507723openalex-snapshot
Progress Towards Therapeutic Small Molecule MEK Inhibitors for Use in Cancer Therapy
inferredcites →https://doi.org/10.2174/157489211795328503openalex-snapshot
Recent Developments in Anti-Cancer Agents Targeting PI3K, Akt and mTORC1/2

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3380254openalex-extracted
Extending the Small Molecule Similarity Principle to All Levels of Biology
inferred← citeshttps://doi.org/10.1002/adtp.202200079openalex-snapshot
Multimodal Therapies against Pancreatic Ductal Adenocarcinoma: A Review on Synergistic Approaches toward Ultimate Nanomedicine Treatments
inferred← citeshttps://doi.org/10.1002/cam4.1091openalex-snapshot
Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal BRAF inhibition
inferred← citeshttps://doi.org/10.1002/cam4.2847openalex-snapshot
Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors
inferred← citeshttps://doi.org/10.1002/mco2.70566openalex-snapshot
Melanoma: Pathogenesis and Targeted Therapy
inferred← citeshttps://doi.org/10.1007/978-3-030-20301-6_6openalex-snapshot
Breast Cancer Heterogeneity in Primary and Metastatic Disease
inferred← citeshttps://doi.org/10.1007/978-3-030-48283-1_6openalex-snapshot
A Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition
inferred← citeshttps://doi.org/10.1007/978-3-031-38605-3_21openalex-snapshot
Current Trends in Treatment and New Generation of Trials in Thyroid Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-91725-2_24openalex-snapshot
Translational Research and Genomics Driven Trials in Thyroid Cancer
inferred← citeshttps://doi.org/10.1007/978-981-13-8719-7_11openalex-snapshot
Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors
inferred← citeshttps://doi.org/10.1007/978-981-15-2361-8_7openalex-snapshot
Targeting the Key Signaling Pathways in Breast Cancer Treatment Using Natural Agents
inferred← citeshttps://doi.org/10.1007/s00280-016-3186-4openalex-snapshot
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037
inferred← citeshttps://doi.org/10.1007/s00280-019-03965-5openalex-snapshot
RETRACTED ARTICLE: NO donor inhibits proliferation and induces apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells
inferred← citeshttps://doi.org/10.1007/s10565-020-09574-wopenalex-snapshot
S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways
inferred← citeshttps://doi.org/10.1007/s10637-019-00776-6openalex-snapshot
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
inferred← citeshttps://doi.org/10.1007/s10637-021-01089-3openalex-snapshot
Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitro
inferred← citeshttps://doi.org/10.1007/s11523-017-0530-5openalex-snapshot
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
inferred← citeshttps://doi.org/10.1007/s13402-018-0409-1openalex-snapshot
Emerging ways to treat breast cancer: will promises be met?
inferred← citeshttps://doi.org/10.1007/s40266-017-0453-yopenalex-snapshot
Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts
inferred← citeshttps://doi.org/10.1016/j.bbcan.2026.189530openalex-snapshot
miRNA-HK2 networks in cancer metabolism: Mechanisms and dual-targeting therapeutic opportunities
inferred← citeshttps://doi.org/10.1016/j.biopha.2016.11.084openalex-snapshot
Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.bmc.2022.116922openalex-snapshot
The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers
inferred← citeshttps://doi.org/10.1016/j.canlet.2018.09.013openalex-snapshot
KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer
inferred← citeshttps://doi.org/10.1016/j.canlet.2019.02.004openalex-snapshot
Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer
inferred← citeshttps://doi.org/10.1016/j.canlet.2019.05.025openalex-snapshot
AKT and ERK dual inhibitors: The way forward?
inferred← citeshttps://doi.org/10.1016/j.ccell.2018.07.012openalex-snapshot
Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses
inferred← citeshttps://doi.org/10.1016/j.cnsns.2020.105586openalex-snapshot
Discrete-time MPC for switched systems with applications to biomedical problems
inferred← citeshttps://doi.org/10.1016/j.ejca.2016.08.026openalex-snapshot
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours
inferred← citeshttps://doi.org/10.1016/j.ejmech.2021.113996openalex-snapshot
Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors
inferred← citeshttps://doi.org/10.1016/j.ejphar.2017.06.030openalex-snapshot
Interference of ursolic acid treatment with glioma growth: An in vitro and in vivo study
inferred← citeshttps://doi.org/10.1016/j.ejphar.2022.175408openalex-snapshot
CFNC, a neocryptolepine derivative, inhibited the growth of gastric cancer AGS cells by inhibiting PI3K/AKT signaling pathway
inferred← citeshttps://doi.org/10.1016/j.fitote.2025.106819openalex-snapshot
Unraveling the active ingredients and molecular mechanisms of Buyi Xiaozheng decoction against ovarian cancer: An integrative approach combining UHPLC-QE-MS, network pharmacology, molecular docking, dynamics simulations, and experimental verification
inferred← citeshttps://doi.org/10.1016/j.ijcard.2018.05.068openalex-snapshot
Extracellular signal-regulated kinase (ERK) activation preserves cardiac function in pressure overload induced hypertrophy
inferred← citeshttps://doi.org/10.1016/j.jconrel.2019.12.019openalex-snapshot
Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment
inferred← citeshttps://doi.org/10.1016/j.jep.2023.117299openalex-snapshot
Research progress on traditional Chinese medicine-induced apoptosis signaling pathways in ovarian cancer cells
inferred← citeshttps://doi.org/10.1016/j.mce.2017.06.002openalex-snapshot
Comparative aspects of GnRH-Stimulated signal transduction in the vertebrate pituitary – Contributions from teleost model systems
inferred← citeshttps://doi.org/10.1016/j.phrs.2016.02.019openalex-snapshot
Using CTCs for pharmacogenomic analysis
inferred← citeshttps://doi.org/10.1016/j.semcdb.2016.06.012openalex-snapshot
The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers
inferred← citeshttps://doi.org/10.1016/j.slasd.2025.100222openalex-snapshot
Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids
inferred← citeshttps://doi.org/10.1016/j.tranon.2016.12.008openalex-snapshot
Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells
inferred← citeshttps://doi.org/10.1016/j.tranon.2024.102045openalex-snapshot
Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors
inferred← citeshttps://doi.org/10.1021/acsptsci.0c00165openalex-snapshot
Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA
inferred← citeshttps://doi.org/10.1021/acsptsci.6c00339openalex-snapshot
Thermal Stability, Plasma Pharmacokinetics, and Tumor Response Modeling of a Cell-Penetrating Protein That Cleaves RAS Family GTPases
inferred← citeshttps://doi.org/10.1038/bjc.2016.220openalex-snapshot
Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer
inferred← citeshttps://doi.org/10.1038/s41388-019-0780-zopenalex-snapshot
Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer
inferred← citeshttps://doi.org/10.1038/s41389-017-0015-5openalex-snapshot
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer
inferred← citeshttps://doi.org/10.1038/s41467-017-02287-5openalex-snapshot
Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality
inferred← citeshttps://doi.org/10.1038/s41540-026-00669-4openalex-snapshot
Experimentally calibrated multiscale model predicts schedule dependent drug combination effects
inferred← citeshttps://doi.org/10.1038/s41587-020-0502-7openalex-snapshot
Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker
inferred← citeshttps://doi.org/10.1038/s41591-018-0022-xopenalex-snapshot
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
inferred← citeshttps://doi.org/10.1038/s41597-019-0255-7openalex-snapshot
A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines
inferred← citeshttps://doi.org/10.1038/s41598-018-28335-8openalex-snapshot
Detection of the Cell Cycle-Regulated Negative Feedback Phosphorylation of Mitogen-Activated Protein Kinases in Breast Carcinoma using Nanofluidic Proteomics
inferred← citeshttps://doi.org/10.1038/srep43013openalex-snapshot
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
inferred← citeshttps://doi.org/10.1074/mcp.tir118.000943openalex-snapshot
A Curated Resource for Phosphosite-specific Signature Analysis
inferred← citeshttps://doi.org/10.1080/08977194.2022.2113394openalex-snapshot
Halofuginone inhibits cell proliferation and AKT/mTORC1 signaling in uterine leiomyoma cells
inferred← citeshttps://doi.org/10.1080/14656566.2020.1798930openalex-snapshot
Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation
inferred← citeshttps://doi.org/10.1080/14728214.2016.1184644openalex-snapshot
Emerging targeted therapies for melanoma
inferred← citeshttps://doi.org/10.1080/15384047.2018.1504718openalex-snapshot
Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells
inferred← citeshttps://doi.org/10.1093/bioinformatics/btac383openalex-snapshot
Looking at the BiG picture: incorporating bipartite graphs in drug response prediction
inferred← citeshttps://doi.org/10.1093/neuonc/nox052openalex-snapshot
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer
inferred← citeshttps://doi.org/10.1093/noajnl/vdz004openalex-snapshot
Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy
inferred← citeshttps://doi.org/10.1101/2023.06.15.545136openalex-snapshot
WITHDRAWN: MEK1/2-Targeting PROTACs Promote the Collateral Degradation of CRAF in KRAS Mutant Cells
inferred← citeshttps://doi.org/10.1101/2024.07.03.601932openalex-snapshot
Influenza A defective viral genomes and non-infectious particles are increased by host PI3K inhibition via anti-cancer drug alpelisib
inferred← citeshttps://doi.org/10.1109/cdc.2018.8619490openalex-snapshot
On the Analysis of Cyclic Drug Schedules for Cancer Treatment using Switched Dynamical Systems
inferred← citeshttps://doi.org/10.1109/socc66126.2025.11235350openalex-snapshot
Low-Power ECG Anomaly Detector Using an Area-Efficient Artificial Neural Network
inferred← citeshttps://doi.org/10.1111/gbb.12440openalex-snapshot
Kinase interest you in treating incubated cocaine‐craving? A hypothetical model for treatment intervention during protracted withdrawal from cocaine
inferred← citeshttps://doi.org/10.1111/jdv.16098openalex-snapshot
Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies
inferred← citeshttps://doi.org/10.1111/jphp.13012openalex-snapshot
Investigation of potent anticarcinogenic activity of 1, 3-diarylpyrazole acrylamide derivatives in vitro
inferred← citeshttps://doi.org/10.1126/scisignal.adx5186openalex-snapshot
Wild-type RAS signaling is an essential therapeutic target in RAS -mutated cancers
inferred← citeshttps://doi.org/10.1126/scitranslmed.aal5253openalex-snapshot
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
inferred← citeshttps://doi.org/10.1158/0008-5472.22419945openalex-snapshot
Merged pdf from ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma
inferred← citeshttps://doi.org/10.1158/0008-5472.22419945.v1openalex-snapshot
Merged pdf from ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma
inferred← citeshttps://doi.org/10.1158/0008-5472.can-15-3425openalex-snapshot
High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells
inferred← citeshttps://doi.org/10.1158/0008-5472.can-18-1001openalex-snapshot
ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-23-1441openalex-snapshot
Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis
inferred← citeshttps://doi.org/10.1158/1535-7163.mct-16-0106openalex-snapshot
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer
inferred← citeshttps://doi.org/10.1158/1535-7163.mct-17-0349openalex-snapshot
Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors
inferred← citeshttps://doi.org/10.1158/1535-7163.mct-19-0858openalex-snapshot
Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma
inferred← citeshttps://doi.org/10.1158/1541-7786.mcr-18-1332openalex-snapshot
Intrinsic Resistance to MEK Inhibition through BET Protein–Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer
inferred← citeshttps://doi.org/10.1158/2159-8290.cd-18-0915openalex-snapshot
Shipping Out MEK Inhibitor Resistance with SHP2 Inhibitors
inferred← citeshttps://doi.org/10.1158/2767-9764.crc-21-0137openalex-snapshot
Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
inferred← citeshttps://doi.org/10.1167/iovs.18-26508openalex-snapshot
Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition
inferred← citeshttps://doi.org/10.1172/jci.insight.177857openalex-snapshot
4EBP1-mediated SLC7A11 protein synthesis restrains ferroptosis triggered by MEK inhibitors in advanced ovarian cancer
inferred← citeshttps://doi.org/10.1172/jci.insight.93313openalex-snapshot
microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer
inferred← citeshttps://doi.org/10.1177/2472555219880194openalex-snapshot
A 3D Heterotypic Multicellular Tumor Spheroid Assay Platform to Discriminate Drug Effects on Stroma versus Cancer Cells
inferred← citeshttps://doi.org/10.1182/blood-2018-08-870089openalex-snapshot
Identification and targeting of novel CDK9 complexes in acute myeloid leukemia
inferred← citeshttps://doi.org/10.1186/s12964-025-02598-xopenalex-snapshot
Host PI3K inhibition via anti-cancer drug alpelisib influences Influenza A non-infectious particles and deletion-containing viral genomes
inferred← citeshttps://doi.org/10.1186/s13045-016-0373-zopenalex-snapshot
Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy
inferred← citeshttps://doi.org/10.1200/po-26-00138openalex-snapshot
Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO
inferred← citeshttps://doi.org/10.14715/cmb/2022.69.1.3openalex-snapshot
Effects of insulin-degrading enzyme on the proliferation of swine Sertoli cells
inferred← citeshttps://doi.org/10.1530/erc-16-0482openalex-snapshot
Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles
inferred← citeshttps://doi.org/10.15698/mic2026.08.885openalex-snapshot
Saccharomyces cerevisiae in cancer research: modeling tumor biology and enabling drug discovery
inferred← citeshttps://doi.org/10.18632/aging.203589openalex-snapshot
RUNX2 and LAMC2: promising pancreatic cancer biomarkers identified by an integrative data mining of pancreatic adenocarcinoma tissues
inferred← citeshttps://doi.org/10.18632/oncotarget.23577openalex-snapshot
The microtubule-associated protein PRC1 is a potential therapeutic target for lung cancer
inferred← citeshttps://doi.org/10.18632/oncotarget.24696openalex-snapshot
Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells
inferred← citeshttps://doi.org/10.18632/oncotarget.26129openalex-snapshot
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer
inferred← citeshttps://doi.org/10.18632/oncotarget.27251openalex-snapshot
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study
inferred← citeshttps://doi.org/10.21007/etd.cghs.2017.0441openalex-snapshot
Genome-scale Precision Proteomics Identifies Cancer Signaling Networks and Therapeutic Vulnerabilities
inferred← citeshttps://doi.org/10.3389/fnmol.2020.560020openalex-snapshot
Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Regulates Neurite Outgrowth Through the Activation of Akt/mTOR and Erk/mTOR Signaling Pathways
inferred← citeshttps://doi.org/10.3389/fonc.2021.811434openalex-snapshot
The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma
inferred← citeshttps://doi.org/10.3389/fphar.2018.00404openalex-snapshot
Emerging Therapies in the Management of Advanced-Stage Gastric Cancer
inferred← citeshttps://doi.org/10.3389/fsysb.2023.1112831openalex-snapshot
Synergistic effects of complex drug combinations in colorectal cancer cells predicted by logical modelling
inferred← citeshttps://doi.org/10.3390/cancers15082373openalex-snapshot
Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma
inferred← citeshttps://doi.org/10.3390/genes12050662openalex-snapshot
The Role of Wild-Type RAS in Oncogenic RAS Transformation
inferred← citeshttps://doi.org/10.3390/ijms18071338openalex-snapshot
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
inferred← citeshttps://doi.org/10.3390/ijms21082956openalex-snapshot
Cutaneous Squamous Cell Carcinoma: From Biology to Therapy
inferred← citeshttps://doi.org/10.3390/ijms21124507openalex-snapshot
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
inferred← citeshttps://doi.org/10.3390/ijms231911924openalex-snapshot
Design, Synthesis and Biological Evaluation of Neocryptolepine Derivatives as Potential Anti-Gastric Cancer Agents
inferred← citeshttps://doi.org/10.3390/ijms241512479openalex-snapshot
Integrated Transcriptome and Molecular Docking to Identify the Hub Superimposed Attenuation Targets of Curcumin in Breast Cancer Cells
inferred← citeshttps://doi.org/10.3390/ijms25042001openalex-snapshot
Cannabigerol Induces Autophagic Cell Death by Inhibiting EGFR-RAS Pathways in Human Pancreatic Ductal Adenocarcinoma Cell Lines
inferred← citeshttps://doi.org/10.3390/jcm8070972openalex-snapshot
Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells
inferred← citeshttps://doi.org/10.5204/thesis.eprints.123437openalex-snapshot
Investigations into how best to target FGFR2 mutant endometrial cancer
inferred← citeshttps://doi.org/10.53846/goediss-7972openalex-snapshot
Network Based Integration of Proteomic and Transcriptomic Data: Study of BCR and WNT11 Signaling Pathways in Cancer Cells
inferred← citeshttps://doi.org/10.70675/0b7bdb5azf42fz42d0z856dz67e069b5b290openalex-snapshot
Détection de l'ADN circulant chez le sujet sain et le patient atteint d'un cancer métastatique par PCR digitale en gouttelettes
inferred← citeshttps://doi.org/10.7314/apjcp.2016.17.4.1649openalex-snapshot
Anti-Cancer Effects of Green Tea by Either Anti- or Pro-Oxidative Mechanisms
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.